4.2
만성 폐쇄성 폐질환(COPD) 병태생리는 복잡하고 다면적이며, 생리적 과정의 복잡한 상호 작용을 포함합니다. 이러한 메커니즘을 이해하는 것은 COPD를 효과적으로 관리하고 치료하는 데 필수적입니다. 다음은 COPD 병태생리학의 중요한 요소에 대한 심층적인 살펴보기입니다…
만성 폐쇄성 폐질환(COPD)은 주로 담배 연기, 먼지 또는 대기 오염과 같은 자극 물질에 대한 노출로 인한 만성 기도 염증으로 인해 발생합니다.
림프구, 대식세포, 호중구를 포함한 염증 세포는 기도벽을 침범하여 류코트리엔과 사이토카인과 같은 유해한 매개체를 방출합니다.
이러한 염증 세포에서 생성된 흡입 입자와 산화제는 염증을 악화시킵니다.
산화제는 폐 조직의 파괴를 방지하는 항프로테아제 화합물을 억제합니다.
동시에 폐 조직을 분해하는 프로테아제 효소의 활성을 증가시킵니다.
이러한 불균형은 프로테아제와 항프로테아제 사이의 자연적인 균형을 깨뜨려 폐포의 악화와 폐 탄력성의 상실로 이어집니다.
그 결과, 기도가 좁아져 공기 흐름이 방해되어 과도한 점액 생성을 촉진하고 폐에 체액이 축적됩니다.
COPD에서 만성 염증은 산화 스트레스를 유발하여 폐 조직을 손상시키는 활성산소를 방출하여 수포성 형성 및 폐포 벽 악화를 유발하여 가스 교환을 손상시킵니다.
View the full transcript and gain access to JoVE Core videos
Q1: What causes chronic airway inflammation in COPD?
COPD develops from chronic exposure to irritants like cigarette smoke, dust, and air pollution. These irritants trigger inflammatory cells—lymphocytes, macrophages, and neutrophils—to infiltrate airway walls and release harmful mediators such as leukotrienes and cytokines. This perpetuates ongoing inflammation and progressive lung damage characteristic of the disease.
Q2: How does the protease-antiprotease imbalance damage lung tissue in COPD?
Oxidants from cigarette smoke impair antiproteases like alpha-1 antitrypsin that normally protect lung tissue. Simultaneously, oxidants increase protease activity, particularly elastase, which degrades extracellular matrix components. This imbalance causes destruction of alveolar walls and lung parenchyma, leading to emphysema and loss of lung elasticity.
Q3: What role do free radicals play in COPD pathophysiology?
Chronic inflammation generates reactive oxygen species (ROS) like superoxide anions and hydroxyl radicals from cigarette smoke and inflammatory cells. These free radicals damage cellular structures, proteins, lipids, and DNA, further promoting inflammation and lung tissue deterioration. This oxidative stress perpetuates the cycle of tissue destruction in COPD.
Q4: How does airway narrowing occur in COPD?
Chronic inflammation causes structural changes and constriction in airways, reducing airflow. Mucus hypersecretion and mucosal edema exacerbate narrowing, while smooth muscle constriction further impedes airflow. Additionally, increased vascular permeability from inflammation leads to fluid accumulation in lungs, contributing to obstruction and airway blockage.
Q5: What structural changes occur in the lungs during COPD?
Ongoing tissue destruction causes alveolar enlargement and bullae formation—large air pockets within lung tissue. Destruction of alveolar walls reduces surface area for gas exchange, impairing oxygen uptake and carbon dioxide elimination. These structural changes decrease lung compliance and elasticity, leading to reduced oxygen uptake and shortness of breath.
Q6: How do inflammatory mediators perpetuate lung damage in COPD?
Inflammatory cells release cytokines, leukotrienes, and other mediators that perpetuate the inflammatory response. These mediators recruit additional inflammatory cells and sustain the release of proteases and oxidants. This creates a self-perpetuating cycle of inflammation and tissue destruction that characterizes COPD progression.
Q7: Why is gas exchange impaired in COPD?
Destruction of alveolar walls reduces the surface area available for oxygen and carbon dioxide exchange. Combined with fluid accumulation and airway obstruction, these structural changes impair gas exchange efficiency. Understanding these mechanisms is essential for developing effective chronic obstructive pulmonary disease management strategies.